RSL3 enhances the antitumor effect of cisplatin on prostate cancer cells via causing glycolysis dysfunction.
Sign Up to like & getrecommendations! Published in 2021 at "Biochemical pharmacology"
DOI: 10.1016/j.bcp.2021.114741
Abstract: The resistance to cisplatin (DDP) and dose-related toxicity are the two important obstacles in the chemotherapy of prostate cancer (PCa) patients. The present study demonstrated that cotreatment of DDP and RSL3, a type of small… read more here.
Keywords: glycolysis dysfunction; ddp; prostate cancer; rsl3 ... See more keywords